No black box warning on record for Xospata

As of the latest FDA labeling reviewed, Xospata (GILTERITINIB) does not carry a black box warning. Standard warnings and precautions still apply — see the full Xospata medicine page for the complete safety profile.

Other warnings & precautions

5 WARNINGS AND PRECAUTIONS • Posterior reversible encephalopathy syndrome (PRES): Discontinue XOSPATA in patients who develop PRES. ( 2.3 , 5.2 , 6.1 ) • Prolonged QT Interval: Interrupt and reduce XOSPATA dosage in patients who have a QTcF >500 msec. Correct hypokalemia or hypomagnesemia prior to and during XOSPATA administration. ( 2.3 , 5.3 , 12.2 , 6.1 ) • Pancreatitis: Interrupt and reduce th

No black box warning on record for Xospata

Other warnings & precautions

5 WARNINGS AND PRECAUTIONS • Posterior reversible encephalopathy syndrome (PRES): Discontinue XOSPATA in patients who develop PRES. ( 2.3 , 5.2 , 6.1 ) • Prolonged QT Interval: Interrupt and reduce XOSPATA dosage in patients who have a QTcF >500 msec. Correct hypokalemia or hypomagnesemia prior to and during XOSPATA administration. ( 2.3 , 5.3 , 12.2 , 6.1 ) • Pancreatitis: Interrupt and reduce th

Xospata Black Box Warning

No black box warning on record for Xospata

Other warnings & precautions

Xospata Black Box Warning

No black box warning on record for Xospata

Other warnings & precautions